Announcement of the impact of an antiviral agent (Remdesivir) against COVID-19 after clinical trials

https://www.gilead.com/news-and-press/press-room/press-releases/2020/4/gilead-announces-results-from-phase-3-trial-of-investigational-antiviral-remdesivir-in-patients-with-severe-covid-19

On 29 April, Anthony Fauci, director of the US National Institute of Allergy and Infectious Diseases (NIAID), announced that a clinical trial in more than 1,000 people had showed that those taking remdesivir recovered in 11 days on average, compared with 15 days for those on a placebo. There were also fewer deaths among trial participants who received the drug, he said, but that trend was not statistically significant. The shortened recovery time, however, was significant.

Link: https://www.nature.com/articles/d41586-020-01295-8